Update on GALT’s GR-MD-02 – Analyst Blog
Galectin Therapeutics Inc. ‘s ( GALT ) carbohydrate based galectin inhibitor GR MD 02 is currently in phase I development …read more
Galectin Therapeutics Inc. ‘s ( GALT ) carbohydrate based galectin inhibitor GR MD 02 is currently in phase I development …read more
Covidien plc ( COV ) announced the receipt of the U.S. Food and Drug Administration (FDA) 510(k) clearance for the …read more
Flying straight in the face of another lackluster overall Tech industry earnings season, Microsoft Corp. ( MSFT ) just posted …read more
Starbuck’s EPS Beat, but CSS DeclinesStarbucks Corp ( SBUX ) reported earnings after the bell today. The bottom line …read more
On Jan 21, 2014, we reaffirmed our long term recommendation on BRE Properties Inc. ( BRE ) a …read more
Automotive retailer Group 1 Automotive Inc. ( GPI ) announced the acquisition of dealerships Heller Ford of …read more
Great Lakes Dredge & Dock Corporation ( GLDD ) announced that it has been awarded a $51.9 million option for …read more
News Corporation ( NWSA ) announced the exit of Lex Fenwick, the chief executive officer (CEO) of Dow Jones & …read more
ABB Ltd. ( ABB ) recently announced that it expects fourth quarter 2013 basic earnings to be 23 cents per …read more
MedAssets, Inc . ( MDAS ) recently announced the renewal of its multi year agreement with Kaiser Permanente, the largest …read more